Zoetis Sees Strong Companion and Livestock Segment Growth in Q4 2025 Call
Zoetis reported robust full-year expansion in its Q4 2025 earnings call, driven by strong companion animal and livestock product sales. Management highlighted improved operating leverage and competitive positioning supporting margin expansion into 2026.
1. Q4 2025 Earnings Call Highlights
Zoetis's Q4 2025 earnings call underscored robust full-year revenue growth, led by outperformance in companion animal vaccines and livestock medications. Management credited improved operating leverage, pricing actions and cost efficiencies for expanding margins despite a competitive industry landscape, and signaled confidence in sustaining momentum into 2026.
Related News
RLAY
Relay Therapeutics Prices 22.9M Shares at $12 to Raise $275M
RLAY•
NVDA
Nvidia Posts 85% Revenue Surge to $81.6B, Forecasts $91B Next Quarter
NVDA•
TOST
Toast Sponsors ICC UK Initiative, Showcases Platform Powering 171,000 Global Locations
TOST•
GOOG
Ackman Cuts Alphabet Stake 95% as Nvidia Forecast Raises Google Cloud Competition
GOOG•
META
Manus Founders Seek $1B Raise to Unwind Meta's $2B AI Acquisition
META•
Sources
F